KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Elanco Animal Health (ELAN) over the last 9 years, with Q3 2025 value amounting to $530.0 million.

  • Elanco Animal Health's Cost of Revenue rose 772.36% to $530.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 247.77%. This contributed to the annual value of $2.0 billion for FY2024, which is 372.86% up from last year.
  • Elanco Animal Health's Cost of Revenue amounted to $530.0 million in Q3 2025, which was up 772.36% from $528.0 million recorded in Q2 2025.
  • Over the past 5 years, Elanco Animal Health's Cost of Revenue peaked at $566.0 million during Q1 2021, and registered a low of $434.0 million during Q2 2023.
  • Over the past 5 years, Elanco Animal Health's median Cost of Revenue value was $502.0 million (recorded in 2021), while the average stood at $502.3 million.
  • The largest annual percentage gain for Elanco Animal Health's Cost of Revenue in the last 5 years was 8614.86% (2021), contrasted with its biggest fall of 1445.82% (2021).
  • Elanco Animal Health's Cost of Revenue (Quarter) stood at $510.0 million in 2021, then dropped by 12.16% to $448.0 million in 2022, then rose by 15.18% to $516.0 million in 2023, then dropped by 2.91% to $501.0 million in 2024, then increased by 5.79% to $530.0 million in 2025.
  • Its Cost of Revenue was $530.0 million in Q3 2025, compared to $528.0 million in Q2 2025 and $509.0 million in Q1 2025.